Actelion buyout could reach $9.8B, Bloomberg figures

Bloomberg sat down to crunch the numbers on a potential takeover of Switzerland's Actelion and concluded that the biotech could fetch around $9.8 billion if Amgen ($AMGN) or some other suitor swoops in to take it over. Report